Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TDO2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TDO2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. Suitable for biochemical screening. |
View TDO2 Products |
| Gene Delivery | TDO2 Lentivirus Premade Particles Full-length ORF for stable cell line generation. Ideal for cell-based kynurenine accumulation assays. |
View TDO2 Products |
| Benchmark Ab | Anti-TDO2 Antibody Recombinant positive control antibody for target validation and expression monitoring. |
View TDO2 Products |
| Validator | TDO2 siRNA Set For specific knockdown verification in tumor cell lines. |
View TDO2 Products |
| Related Target A | IDO1 Primary tryptophan-degrading enzyme. Critical for selectivity profiling and dual-inhibitor development. |
View IDO1 Products |
| Related Target B | AhR (Aryl Hydrocarbon Receptor) Downstream transcription factor activated by kynurenine, mediating immunosuppression. |
View AhR Products |
| Related Target C | IDO2 IDO1 homolog involved in immune modulation. Essential counter-screening target. |
View IDO2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling (TDO2 vs. IDO1/IDO2) | Sequence-verified human TDO2, IDO1, and IDO2 recombinant proteins available with >95% purity for robust comparative assay design. |
| Cell-based functional validation | High-titer Lentivirus Premade Particles for stable overexpression of TDO2 to measure extracellular kynurenine flux. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-specificity siRNA sets included for system validation. |
| False Positives in Enzymatic Screening | Endotoxin-controlled, highly pure recombinant proteins minimize background interference in spectrophotometric assays. |
Live TDO2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TDO2 therapeutics is intensifying, with major players shifting focus from traditional mono-targeting to dual IDO1/TDO2 inhibitors and combination regimens with immune checkpoint inhibitors (PD-1/PD-L1). As first-generation IDO1 single-target therapies faced clinical efficacy bottlenecks, the next wave of R&D is targeting the TDO2 pathway to overcome IDO1-inhibitor resistance and address highly immunosuppressive solid tumors, particularly glioblastoma, bladder cancer, and triple-negative breast cancer (TNBC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Merck, Bristol Myers Squibb, iTeos Therapeutics | Glioblastoma, Melanoma, Solid Tumors | Enzymatic Selectivity Assay (Need highly purified, sequence-verified TDO2, IDO1, and IDO2 proteins) |
| Dual IDO1/TDO2 Inhibitors | Incyte, Roche | Advanced Refractory Solid Tumors | Parallel Screening Panels (Need concurrent validation with IDO1 and TDO2 targets) |
| Combination Therapies | Academic Institutes, Biotech Consortia | Checkpoint Inhibitor Resistant Cancers | Stable Overexpression Models (Need Lentivirus for stable cell line generation to evaluate combination efficacy) |